biostudies-literatureHuan XShanghai Municipal Hospital Development CenterNational Natural Science Foundation of ChinaNational Key Research and Development Program of Chinae70513https://www.ebi.ac.uk/biostudies/studies/S-EPMC12836041biostudies-literatureUnknown33(2)<h4>Background</h4>Myasthenic crisis (MC) affects 10%-20% of myasthenia gravis patients and is life-threatening with significant economic burden, yet its long-term outcomes remain poorly understood. This prospective multicentre study aimed to evaluate 1-year clinical outcomes after MC.<h4>Methods</h4>This study enrolled patients with MC between December 2018 and October 2024 and prospectively followed at 1, 2, 3, 6, and 12 months post-MC. Outcome measures included Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) classification at 1 year after MC, all-cause mortality, and complications.<h4>Results</h4>The cohort comprised 277 patients with 282 MC episodes with a follow-up duration of 29.16 ± 15.93 months. The in-hospital mortality was 5.05% (14/277), while the alEuropean journal of neurology1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China.PMC12836041824714262022YFC35013052022YFC3501303SHDC2023CRD007Ruan ZZhang HJiang QBu BDeng HZheng JLiu YXi JZou ZJia WWang YWu WChen RXi CZhou HJin LYang HYang LZhao CHuan XChinese Myasthenia Gravis Collaborating Group (CMGCG)Chang TYang CSong JLi WLi YGuan YDa YLuo LDuan RTan SZhong HYan CShi JLuo SYang SYue YXu Yfalse1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China.<h4>Background</h4>Myasthenic crisis (MC) affects 10%-20% of myasthenia gravis patients and is life-threatening with significant economic burden, yet its long-term outcomes remain poorly understood. This prospective multicentre study aimed to evaluate 1-year clinical outcomes after MC.<h4>Methods</h4>This study enrolled patients with MC between December 2018 and October 2024 and prospectively followed at 1, 2, 3, 6, and 12 months post-MC. Outcome measures included Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) classification at 1 year after MC, all-cause mortality, and complications.<h4>Results</h4>The cohort comprised 277 patients with 282 MC episodes with a follow-up duration of 29.16 ± 15.93 months. The in-hospital mortality was 5.05% (14/277), while the al2026-01-01T00:00:00Z2026 Feb2026-06-14T03:13:01.018Z2026-06-14T03:08:52.132ZS-EPMC128360414158941810.1111/ene.70513